We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Rare Infection in Transplant Recipients Linked to Donors

By LabMedica International staff writers
Posted on 01 Jun 2017
Print article
Image: Mycoplasma hominis, the bacteria responsible for a rare infection in transplant recipients (Photo courtesy of the Mayo Clinic).
Image: Mycoplasma hominis, the bacteria responsible for a rare infection in transplant recipients (Photo courtesy of the Mayo Clinic).
The way in which heart and lung transplant recipients acquired a specific species of bacteria, Mycoplasma hominis, had been previously undefined, and the bacterium was difficult to test for and detect. Originally, this bacterium was considered to reside exclusively in, and be a potential pathogen of the area of the reproductive and urinary organs.

M. hominis resists most antibiotics, and the three antibiotic treatment recommendations for these infections are neither standard for post-transplant recipient care nor are they standard in therapy regimens for surgical site infections. Heart and lung transplant recipient infection caused by M. hominis may present with, surgical site infection and mediastinitis, which is an inflammation of tissue in mid-chest.

Scientists at the Mayo Clinic investigated lung and heart-lung transplants between 1998 and July 2015 at the Mayo Clinic. Seven previously unreported cases of transplant recipients with M. hominis infection were discovered. In each case, pre-transplant sputum cultures had tested negative for M. hominis. A literature review since 1950 found 15 cases of M. hominis infection in lung, heart or heart-lung transplant recipients. The way the bacteria spread remained uncertain. Given its normal residence in the genitourinary tract, some speculated that infection arose from urinary catheter placement during the transplant surgery.

Bronchoalveolar lavage samples were submitted for detecting organisms commonly found in immunocompromised hosts undergoing clinically indicated bronchoscopy were tested for M. hominis DNA. DNA was extracted on the MagNA Pure LC instrument using the MagNA Pure total nucleic acid isolation kit. Common testing methods have proven insufficient in identifying the bacteria, but the use of polymerase chain reaction offered a more time-sensitive and specific test for the bacteria. With this method, the scientists were able to focus in on a certain portion of DNA and then create multiple copies to amplify the segment. Polymerase chain reaction detection reduces the time to detect M. hominis to a few hours, compared to the two to five days needed for a culture media test.

Mark E. Wylam, MD, the lead investigator said, “These findings could affect how we approach the evaluation of organ donors. If potential transmission of these harmful bacteria can be identified and addressed, the recipient will face a decreased risk of infection and its serious complications. This study shows us that surveillance of both donor and recipient are important in recognizing M. hominis and the infection it can cause.” The study was published in the May 2017 issue of the journal EbioMedicine.

New
Platinum Member
Flu SARS-CoV-2 Combo Test
OSOM® Flu SARS-CoV-2 Combo Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
New
Gold Member
Liquid Ready-To-Use Lp(a) Reagent
Lipoprotein (a) Reagent

Print article

Channels

Clinical Chemistry

view channel
Image: The new ADLM guidance will help healthcare professionals navigate respiratory virus testing in a post-COVID world (Photo courtesy of 123RF)

New ADLM Guidance Provides Expert Recommendations on Clinical Testing For Respiratory Viral Infections

Respiratory tract infections, predominantly caused by viral pathogens, are a common reason for healthcare visits. Accurate and swift diagnosis of these infections is essential for optimal patient management.... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Microbiology

view channel
Image: The POC PCR test shortens time for STI test results (Photo courtesy of Visby Medical)

POC STI Test Shortens Time from ED Arrival to Test Results

In a 2024 sexually transmitted infections (STIs) surveillance report by the World Health Organization (WHO), over 2.5 million cases were recorded, alongside a rise in the inappropriate use of antibiotics... Read more

Industry

view channel
Image: For 46 years, Roche and Hitachi have collaborated to deliver innovative diagnostic solutions (Photo courtesy of Roche)

Roche and Hitachi High-Tech Extend 46-Year Partnership for Breakthroughs in Diagnostic Testing

Roche (Basel, Switzerland) and Hitachi High-Tech (Tokyo, Japan) have renewed their collaboration agreement, committing to a further 10 years of partnership. This extension brings together their long-standing... Read more
LGC Clinical Diagnostics